Wegovy Gets Provisional Approval for Severe Fatty Liver Disease
01 Apr 2026
GPs can prescribe it for patients with moderate to advanced liver fibrosis (F2–F3 stages).
The approval is based on evidence that Wegovy can reduce liver inflammation and improve fibrosis, though ongoing trials will be needed to confirm long-term benefits. Experts say the drug gives doctors a new option for early intervention, which is important because many people with MASH have no symptoms until liver damage becomes serious.With MASH cases projected to increase, the TGA has provisionally approved Wegovy (semaglutide) for adults with moderate to advanced liver fibrosis. This gives GPs a new tool for early intervention in a condition that often shows no symptoms until liver damage is severe.
Dr Gary Deed highlighted links between MASH and obesity, type 2 diabetes, and other metabolic conditions. Early action can prevent progression to cirrhosis and liver cancer. Experts urge GPs to assess at-risk patients and combine medication with lifestyle support.
https://www1.racgp.org.au/
Source: TGA / RACGP / Novo Nordisk